7. M. Agrawal, S. Saraf, S. Saraf, S. G. Antimisiaris, M. B. Chougule, S. A. Shoyele and A. Alexander, Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs, J. Control. Release281 (2018) 139–177; https://doi.org/10.1016/j.jconrel.2018.05.01110.1016/j.jconrel.2018.05.01129772289
9. L. C. Espinoza, M. Vacacela, B. Clares, M. L. Garcia, M. J. Fabrega and A. C. Calpena, Development of a nasal donepezil-loaded microemulsion for the treatment of Alzheimer’s disease: in vitro and ex vivo characterization, CNS Neuro. Disord. Drug Targets17 (2018) 43–53; https://doi.org/10.2174/187152731766618010412234710.2174/187152731766618010412234729299992
11. A. K. Al Asmari, Z. Ullah, M. Tariq and A. Fatani, Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil, Drug Des. Devel. Ther. 10 (2016) 205–215; https://doi.org/10.2147/DDDT.S9393710.2147/DDDT.S93937
15. L. E. Jabarian, M. R. Rouini, F. Atyabi, A. Foroumadi, S. M. Nassiri and R. Dinarvand, In vitro and in vivo evaluation of an in situ gel forming system for the delivery of PEGylated octreotide, Eur. J. Pharm. Sci. 48 (2013) 87–96; https://doi.org/10.1016/j.ejps.2012.09.01710.1016/j.ejps.2012.09.017
17. M. Valis, J. Masopust, O. Vysata, J. Hort, R. Dolezal, J. Tomek, J. Misik, K. Kuca and J. Z. Karasova, Concentration of donepezil in the cerebrospinal fluid of AD Patients: Evaluation of dosage sufficiency in standard treatment strategy, Neurotox. Res. 31 (2017) 162–168; https://doi.org/10.1007/s12640-016-9672-y10.1007/s12640-016-9672-y
19. H. M. Fan, Z. X. Cong and F. G. Gu, Preparation and in vitro properties of thermosensitive in situ nasal gel of donepezil hydrochloride, Centr. South Pharm. 16 (2018) 1194–1199; https://doi.org/10.7539/j.issn.1672-2981.2018.09.003 (in Chinese only)